Lipid Nanoparticle Composition for Nebulization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Delivering mRNA therapeutics to the lungs via nebulization is challenging due to natural barriers and the entrapment of particles by lung mucus, which reduces the effectiveness of lipid nanoparticles.
Innovation Solution
The development of lipid nanoparticles with a lower total lipid content, specifically by reducing the molar ratio of non-cationic lipids and increasing the molar ratio of cationic lipids to greater than 40%, improves nebulization output rates and maintains encapsulation efficiency, achieving enhanced protein expression of mRNA-encoded proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the total lipid content in lipid nanoparticles is increased to improve mRNA encapsulation, then the encapsulation efficiency is improved, but the nebulization output rate decreases
Solution Approach 1:
The patent applies parameter changes by optimizing the lipid:mRNA ratio to 19:1 or less and adjusting the molar ratio of cationic lipid to greater than 40%, thereby changing the physical and chemical properties of the lipid nanoparticles to achieve both high encapsulation efficiency and improved nebulization output rate
Solution Approach 2:
The patent uses composite materials by formulating lipid nanoparticles with specific combinations of cationic lipid, non-cationic lipid, PEG-modified lipid, and cholesterol in optimized ratios, creating a composite structure that balances encapsulation capability with nebulization performance
2Stability of the object's composition
If the molar ratio of non-cationic lipid is increased to stabilize the lipid nanoparticle structure, then the structural stability is improved, but the nebulization output rate and protein expression decrease
Solution Approach 1:
The patent applies parameter changes by reducing the molar ratio of non-cationic lipid and increasing the molar ratio of cationic lipid to greater than 40%, thereby optimizing the structural parameters to achieve both stability and improved nebulization performance
3Quantity of substance
If large amounts of intact lipid nanoparticles are delivered to achieve therapeutic protein expression, then the protein expression is improved, but the delivery efficiency through nebulization decreases due to particle entrapment by lung mucus
Solution Approach 1:
The patent applies parameter changes by optimizing the lipid nanoparticle composition and size parameters, reducing total lipid content while maintaining encapsulation efficiency, thereby improving nebulization output rate and delivery efficiency to overcome mucus entrapment
Solution Approach 2:
The patent applies partial action by using reduced total lipid content in the lipid nanoparticles, which is sufficient to achieve effective mRNA delivery and protein expression without the excessive lipid content that would hinder nebulization and increase mucus entrapment
Data Source
AI summary
The present invention provides, among other things, improved mRNA-encapsulating lipid nanoparticles that are particularly effective for pulmonary delivery by nebulization. The lipid nanoparticles comprise a lipid component consisting of a cationic lipid, a non-cationic lipid, a PEG-modified lipid, and a cholesterol or cholesterol analogue with a lower molar ratio of the non-cationic lipid than is typically present in lipid nanoparticles delivered via this route of administration.